AH0003

A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (金禾娱乐城0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period

Brief summary

The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer’s Disease (AD).

Medical Condition

Alzheimer’s Disease

Min. Age

50
Years

Max. Age

80
Years

Who Can Join?

All

Status

Active, not recruiting
Inclusion criteria

- 50 to 80 years of age - Diagnosis of prodromal/mild cognitive impairment (MCI) due to Alzheimer’s Disease (AD) or mild AD according to National Institute of Aging-Alzheimer’s Association (NIA-AA) -A global Clinical Dementia Rating (CDR) score of 0.5 to 1.0 and CDR-Memory Box (CDRMB) score ≥0.5 at Screening and Baseline - Score of ≤85 for the delayed recall domain of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at Screening - Mini-Mental State Examination (MMSE) score ≥20 at Screening - Participant has an identified informant that has and will maintain sufficient contact (minimum of 5 hours per week) with the participant to be able to provide accurate information on the participant’s cognitive, functional, and emotional states and of the participant’s personal care - At least 6 years of formal education after the age of 5 or work experience to exclude mental deficits other than prodromal or mild AD dementia - Evidence of cerebral Aβ accumulation by either positive amyloid assessment by either positron emission tomography (PET) scan or cerebrospinal fluid pTau181/Aβ1-42 ratio assessment

Exclusion criteria

- Any evidence of a condition that may affect cognition other than AD - Contraindications to PET imaging - Inability to tolerate or contraindication to magnetic resonance imaging - Any serious medical condition or abnormality that in the opinion of the investigator would preclude safe participation in and completion of the study or interfere with study assessments and/or study interpretation - Alcohol or drug abuse within 2 years of screening - Use of any experimental therapy within the past 6 months (or 5 half lives) prior to screening - Previous treatment with medication intended to treat a neurodegenerative disorder (other than AD) within 1 year of screening - Chronic daily treatment with atypical antipsychotics, opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally acting antihistamine or anticholinergic activitiy - Received treatment with monoclonal antibodies (mAbs), cytokines, immunoglobulins, or other blood products within 3 months or 5 half-lives (whichever is longer) prior to first dosing

Study Medication Description

Study Medication:

Bepranemab

Other Descriptive Name:

bepranemab

Placebo

Yes

Comparator:

No

Study Dates

June 2021

Actual Start Date of Enrollment

July 2025

Planned Study Completion Date

General Information

Study ID:
AH0003
EudraCT Number:
CT.gov Number:
Phase:
Phase 2

Locations

Interested in our clinical studies?

Just contact us

Austria

金禾娱乐城Cares.AT@ucb.com
+43 (0) 1 291 80 08
0800-296176 (freephone)

Belgium

金禾娱乐城Cares.BE@ucb.com
+32 2 559 92 00
0800 38 008 (freephone)

Bulgaria

Canada

+1 866 709 8444

Czech Republic

金禾娱乐城Cares.CZ@ucb.com
+420 221 773 442
800 144 395 (freephone)

Denmark

金禾娱乐城Cares.DK@ucb.com
+45 32462480
80 253827 (freephone)

Finland

金禾娱乐城Cares.FI@ucb.com
+358 942733300
0800 9 13353 (freephone)

France

金禾娱乐城Cares.FR@ucb.com
+33 1 47 29 45 55
0 805 222 949 (freephone)

Germany

Greece

金禾娱乐城Cares.GR@ucb.com
+30 21 0997 4200
0080 012 9910 (freephone)

Hungary

金禾娱乐城Cares.HU@ucb.com
+36 1 472 5060
06 80 021 486 (freephone)

Ireland

金禾娱乐城Cares.IE@ucb.com
+353 1 463 2371
1800 93 00 75 (freephone)

Italy

金禾娱乐城Cares.IT@ucb.com
+39 02 3007 9300
8009-86932 (freephone)

Japan

Luxemburg

金禾娱乐城Cares.LU@ucb.com
+32 2 559 92 12
8002 3204 (freephone)

Norway

金禾娱乐城Cares.NO@ucb.com
+45 32462482
800-10101 (freephone)

Poland

金禾娱乐城Cares.PL@ucb.com
+48 22 596 97 97
00 800 121 68 25 (freephone)

Portugal

金禾娱乐城Cares.PT@ucb.com
+351 213 025 300
800-8-56033 (freephone)

Romania

+4021 300 19 07

Slovakia

金禾娱乐城Cares.SK@ucb.com
+421 2 592 020 23
0800 002 566 (freephone)

Spain

金禾娱乐城Cares.ES@ucb.com
+34 915 70 06 49
8000-99684 (freephone)

Sweden

金禾娱乐城Cares.SE@ucb.com
+45 32462481
0200 898 671 (freephone)

Switzerland

+41 58 822 3180

The Netherlands

金禾娱乐城Cares.NL@ucb.com
+31 76 573 1130
0800 3434335 (freephone)

UK

金禾娱乐城Cares.UK@ucb.com
+44 1753 777 100
0800 279 3177 (freephone)

USA